

Innovative Therapeutic Targets, Drugs, Disease Mechanisms and Technologies in Neuroscience

Takeda Pharmaceutical are launching an open innovation initiative, inviting researchers to submit their ideas and technologies across five different focus areas, **up to £85k / €100k / \$150k (AUD)**. Summarised below are the interests of Takeda relating to therapeutic targets, drugs, disease mechanisms and technologies in Neuroscience. In the attached application form, each of these topics have been expanded upon to give further detail of proposals.



Submissions should be relevant to one or more of the following titles:

- REF#1: Proposal and validation study of novel therapeutic approaches for rare/intractable diseases associated with neurodegeneration; e.g. ALS, Huntington's disease and ataxias
- REF#2: Research on cellular senescence in neurodegenerative and neurodevelopmental diseases
- REF#3: Research on pathophysiology of blood-brain barrier (BBB) in neurodegenerative diseases
- REF#4: Research on non-demented with Alzheimer's neuropathology
- REF#5: Research on cell therapy for central nervous system
- REF#6: Research on physiological and pathological significance of iron accumulation in neurodegenerative diseases
- REF#7: Ideas on novel small molecule therapeutics for congenital muscle diseases such as muscular dystrophies (DMD, DM1, etc.) or congenital myopathies
- REF#8: Ideas on novel small molecule therapeutics for hereditary neuropathies including Charcot-Marie-Tooth (CMT) disease, spinal and bulbar muscular atrophy (SBMA), or congenital myasthenic syndrome (CMS), etc.
- REF#9: Establishment of neuroinflammation related cellular model/animal model and strategy for patient stratification for inhibitor of innate immune system
- REF#10: Novel therapeutic approach to prevent or recover age-related disturbance of neuronal function; e.g. sleep/circadian rhythm, waste clearance, BBB integrity, inflammation, organelle homeostasis, DNA damage
- REF#11: Novel methods to enhance clearance system of abnormal proteins from brain, glymphatic system
- REF#12: Drug discovery research and translational research for white matter damage in neurodegenerative disease

Jurisdictions of Interest

Only submissions from **Europe** and **Australia** will be eligible for this campaign.

Submission Information

To view more details on each area of interest seeking proposals for funding, **download an application form here**. To submit your proposal, please visit **discover.in-part.com**, register, and submit as a Research Project under the appropriate Discover campaign.

Opportunities sought

- Research projects

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **29th July 2021 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk



Takeda is a global pharmaceutical company focused on solving unmet needs in the areas of oncology, gastroenterology, neuroscience and rare diseases. They have an extensive history of successful collaborations with universities and academic institutions worldwide.

